Gal3 has been implicated as a contributor to many of the aggressive features associated with basic tumor patho-biology including, but not limited to metastatic and invasive potential, immune suppression, and treatment resistance in some solid tumors, such as breast and prostate cancer [12, 40, 50]. This evidence concerns the gene LGALS3 and prostate carcinoma.